Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease

Participants needed: 70
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Yehui TanUpdated: Aug 8, 2025Locations: 1
Eligibility criteria

Newly diagnosed AML patients confirmed by bone marrow morphology and immunopheno... [+8]

Acute promyelocytic leukemia (APL). [+14]

Read more
Status: Recruiting

Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly

Participants needed: 68
Trial details
Phase: Phase 3Age: 60-75Biological sex: AllType: InterventionalSponsor: Yehui TanUpdated: Aug 8, 2025Locations: 1
Eligibility criteria

Total bilirubin ≤ 1.5 times the upper limit of normal for the same age group; [+3]

Allergic to any drugs included in the trial protocol or drugs with a chemical st... [+6]

Read more
Status: Recruiting

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)

Participants needed: 46
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Yehui TanUpdated: Aug 8, 2025Locations: 1
Eligibility criteria

Newly diagnosed MDS confirmed by morphological and immunophenotypic analysis of... [+11]

Extramedullary disease involvement； [+9]

Read more